Author:
Pintos-Morell Guillem,Beck Michael
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology, and Child Health
Reference77 articles.
1. Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105:2812–2817
2. Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86
3. Beck M (2006) Demographics of FOS: the Fabry outcomes survey. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis, Oxford, UK, pp 155–161
4. Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838–844
5. Bodamer OA, Ratschmann R, Paschke E et al (2004) Recurrent acroparaesthesia during febrile infections. Lancet 363:1698
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献